Enveric Biosciences Files S-1 Registration

TL;DR

Enveric Biosciences just filed an S-1, looks like they're raising capital soon.

AI Summary

Enveric Biosciences, Inc. filed an S-1 registration statement with the SEC on September 4, 2024. The company, incorporated in Delaware, is in the pharmaceutical preparations industry (SIC code 2834). Its principal executive offices are located at 4851 Tamiami Trail N, Suite 200, Naples, FL 34103. The filing is part of the company's process to register securities for public offering.

Why It Matters

This S-1 filing indicates Enveric Biosciences is preparing to offer new securities to the public, which could impact its stock price and provide capital for its operations.

Risk Assessment

Risk Level: medium — S-1 filings are often associated with potential stock dilution and market uncertainty as companies seek to raise capital.

Key Numbers

• 333-281934 — SEC File Number (Identifies this specific registration statement)
• 20240904 — Filing Date (Date the S-1 was officially filed with the SEC)

Key Players & Entities

• Enveric Biosciences, Inc. (company) — Registrant
• 2834 (dollar_amount) — Standard Industrial Classification Code for Pharmaceutical Preparations
• 954484725 (dollar_amount) — IRS Employer Identification Number
• 4851 Tamiami Trail N, Suite 200, Naples, FL 34103 (dollar_amount) — Principal Executive Offices Address
• Joseph Tu (person) — Mentioned in filing

FAQ

Key Financial Figures

• $0.01 — 0 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund
• $9,422,346 — urchase Agreement", providing for up to $9,422,346 of gross proceeds. See "The Lincoln P
• $577,654 — ment for a total gross cash proceeds of $577,654. Lincoln Park may sell the shares of
• $0.51 — stock on Nasdaq on August 30, 2024 was $0.51 per share. We are a "smaller reportin
• $10.0 million — l to Lincoln Park up to an aggregate of $10.0 million of our common stock from time to time o
• $0 — common stock if the price is not below $0.10, up to 30,000 shares if not below $5
• $5 — $0.10, up to 30,000 shares if not below $5.00, and up to 35,000 if the price is no
• $10 — up to 35,000 if the price is not below $10.00, subject to a maximum commitment of
• $500,000 — .00, subject to a maximum commitment of $500,000 per purchase, which we refer to in this

Filing Documents

• forms-1.htm (S-1) — 473KB
• ex5-1.htm (EX-5.1) — 18KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107.htm (EX-FILING FEES) — 20KB
• forms-1_001.jpg (GRAPHIC) — 5KB
• ex5-1_003.jpg (GRAPHIC) — 3KB
• ex5-1_004.jpg (GRAPHIC) — 13KB
• ex5-1_005.jpg (GRAPHIC) — 5KB
• 0001493152-24-035018.txt ( ) — 845KB
• envb-20240830.xsd (EX-101.SCH) — 3KB
• envb-20240830_def.xml (EX-101.DEF) — 30KB
• envb-20240830_lab.xml (EX-101.LAB) — 36KB
• envb-20240830_pre.xml (EX-101.PRE) — 27KB
• forms-1_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS 8 THE LINCOLN PARK TRANSACTION 9

USE OF PROCEEDS

USE OF PROCEEDS 13 SELLING STOCKHOLDER 14

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 15 PLAN OF DISTRIBUTION 18 LEGAL MATTERS 19 EXPERTS 20 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 21 WHERE YOU CAN FIND MORE INFORMATION 22 ii ABOUT THIS PROSPECTUS This prospectus forms part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, and that includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings "Where You Can Find More Information" and "Incorporation of Certain Information by Reference" before making your investment decision. You should rely only on the information provided in this prospectus or any free writing prospectuses or amendments thereto. Neither we, nor the selling stockholder, have authorized anyone else to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus is accurate only as of the date hereof. Our business, financial condition, results of operations and prospects may have changed since that date. Neither we, nor the selling stockholder, are offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United States. 1 PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus and does not contai

View Full Filing

View this S-1 filing on SEC EDGAR